1 / 8

Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan

Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan. CHA 2 DS 2 -VASc. maximum score is 9 since age may contrubute 0, 1, or 2 points. Lip GY, et al., Chest 137, 263-272, 2010. CHA 2 DS 2 -VASc – overall event rates. 6. 5. 4. 3. 2. 1. 0.

fausto
Download Presentation

Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Insights of the RE-LY CHA2DS2-VASc subgroup analysisHisao OgawaKumamoto University, Japan

  2. CHA2DS2-VASc maximum score is 9 since age may contrubute 0, 1, or 2 points Lip GY, et al., Chest 137, 263-272, 2010

  3. CHA2DS2-VASc – overall event rates 6 5 4 3 2 1 0 0-1 634 2 3408 3 5365 4 4378 5 2566 6 1185 7 451 8-9 125 CHA2DS2-VASc No of patients Stroke and systemic embolism %/year

  4. CHA2DS2-VASc – overall event rates 8 7 6 5 4 3 2 1 0 0-1 634 2 3408 3 5365 4 4378 5 2566 6 1185 7 451 8-9 125 CHA2DS2-VASc No of patients Major (including intracranial) bleeding %/year Intracranial Major

  5. The Net Clinical Benefit of warfarin by CHADS2score CHADS2score 2.22 4-6 0.58 3.75 2.07 3 1.21 2.79 0.97 2 0.43 1.41 0.19 1 -0.27 0.45 -0.11 0 -0.44 -0.20 -1 -0.5 0 0.5 1 1.5 2 2.5 3 3.5 Worse with Warfarin Better with Warfarin Singer DE, et al. : Ann Intern Med. 151, 297-305, 2009

  6. Stroke and systemic embolism (SE) D110 BID vs. warfarin D150 BID vs. warfarin Annual rate, % CHA2DS2-VASc D110 D150 Warfarin 0.8 0.9 0.5 ≤2 3 1.4 1.3 0.8 2.0 4 1.6 1.0 2.8 5-9 2.4 2.1 p(inter)=0.60 p(inter)=0.81 0.50 1.00 1.50 0.50 1.00 1.50 Dabigatran better Warfarin better Dabigatran better Warfarin better

  7. Intracranial bleeding D110 BID vs. warfarin D150 BID vs. warfarin Annual rate, % CHA2DS2-VASc D110 D150 Warfarin ≤2 0.15 0.11 0.38 3 0.16 0.32 0.76 4 0.29 0.21 1.04 5-9 0.32 0.63 0.84 p(inter)=0.09 p(inter)=0.77 0.50 1.00 1.50 0.50 1.00 1.50 Warfarin better Dabigatran better Warfarin better Dabigatran better

  8. Conclusion • Increasing CHA2DS2-VASc scores are associated with raised risks for stroke and bleeding, • Irrespective of CHA2DS2-VASc scores dabigatran 150 mg was superior and dabigatran 110 mg non-inferior to warfarin for stroke prevention • Both dabigatran doses reduce intracranial bleeding irrespective of CHA2DS2-VASc scores Dabigatran has a favorable benefit risk profile compared to warfarin in patients with low to high CHA2DS2-VASc scores

More Related